I virtually attended five sessions on day one of the SGO Annual Meeting - the Opening Ceremony, News We Can All use (Plenary), Moving the Needle (Plenary), Science to Drive Purpose(Plenary) and Together We Tackle Cancer Rapid Fire Poster Sessions. (Saturday March 16,2024.)
Please be patient while reading this post since it may take some time for all the X posts and photos to download.
I'm going to start this post by giving a shout out to the patients and advocates involved in presenting on Saturday. Check out Susan, Linda, Shawn and Jennifer!
#SGOMtg #gyncsm
— Dee Sparacio (@womenofteal) March 16, 2024
Way to go Susan! Yet another survivor/patient advocate presenting. https://t.co/xdhrKoxsgh
#gyncsm And we have another amazing survivor advocate Linda Ryan speaking at the #SGOmtg . Great job Linda! https://t.co/ySh3vXiidz
— Dee Sparacio (@womenofteal) March 17, 2024
Shawn Smith @Ecana speaking- need to close diversity gap. All pts should have access to immunotherapy medicines given great progress for#endometrialcancer @sgo @GOG @gyncsm @IGCSociety @NRGonc @ASCO #PowerofSharedPurpose pic.twitter.com/G6eTEhyn04
— Bhavana Pothuri (@BPothuri) March 16, 2024
Patient Perspective on Tisotumab Vedotin
— Dee Sparacio (@womenofteal) March 16, 2024
Grateful Jennifer Clark could share her experience with TV during the Plenary session.
She celebrated so many milestones after her treatment-
Thanks to the research being done by @SGO_org members! #gyncsm #SGOmtg pic.twitter.com/jWE2gcHmY6
Here are just a few of the 60 tweets & retweets I shared during the Saturday meeting.
Endometrial Cancer
"Overall survival among patients w/ primary adv or recurrent endometrial cancer treated w/ dostarlimab + chemo in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial" Dr Powell: 31% improvement in survival , 16.4 month improvement in median survival, safety maintained #SGOmtg #gyncsm pic.twitter.com/aHu4ioYVOK
— Dee Sparacio (@womenofteal) March 16, 2024
OS & PFS by PD-L1 status in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial, Dr Eskander
— Dee Sparacio (@womenofteal) March 16, 2024
Pembro improved PFS #gyncsm #SGOmtg pic.twitter.com/KzUU4nU5ik
Dostarlimab + chemotherapy followed by dostarlimab plus niraparib maintenance therapy in patients w/ primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial, Dr Mirza
— Dee Sparacio (@womenofteal) March 16, 2024
Potential role of PARP maintenance MMR proficient disease
#SGOmtg #gyncsm pic.twitter.com/aMvYRfplnI
Ovarian Cancer
Raludotatug deruxtecan (R-DXd) monotherapy in patients w prev treated ovarian cancer : subgroup analysis of a first-in-human ph 1 study #gyncsm #SGOmtg
— Dee Sparacio (@womenofteal) March 16, 2024
Pre treated OC , R-DX-d is Antibody drug conjugate ,AE low gr GI, med DOR 11.2 , med PFS 8 months.
New Trial enrolling! pic.twitter.com/4jqKGOitWh
Second very promising #ADC in platinum resistant #ovariancancer of R-Dxd with impressive 49% ORR and 97% DCR but WOW an impressive 6wks to response with duration of 11months!!!! REJOICE confirmatory trial is next! #SGOmtg @SGO_org #gyncsm pic.twitter.com/yksLUDx7uZ
— Dr.Monica Avila (@MAvilaMD) March 16, 2024
HER -2 Expressing Tumors
Efficacy &safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study Dr Makker Small numbers of patients 1/2 #gyncsm #SGOmtg pic.twitter.com/IeTS4kDN3T
— Dee Sparacio (@womenofteal) March 16, 2024
Cervical Cancer
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study Dr Duska #gyncsm #SGOMtg
— Dee Sparacio (@womenofteal) March 16, 2024
1st interim analysis 1/2 pic.twitter.com/wXbmw5LF6F
Efficacy and Safety of Tisotumab Vedotin Versus Investigator's Choice of Chemo in 2L or 3L Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT-cx12/GOG-3057): Dr @GynCancerMD #gyncsm #SGOmtg
— Dee Sparacio (@womenofteal) March 16, 2024
ADC treatment, Improvement in OS 11.5mo TV vs 9.5 mo chemo, Imp efficacy pic.twitter.com/hgRYRSReK7
Ovarian Cancer
Interim Post-Progression Data and Updated Survival in Patients with Newly Diagnosed Advanced Ovarian Cancer in ATHENA-MONO Kristeleit
— Dee Sparacio (@womenofteal) March 16, 2024
3 yrs follow-up Rucaparib benefit extends beyond completion of treatment #gyncsm #SGOmtg pic.twitter.com/TVeDN06kMi
Patient-Reported Outcome Results from Phase III MIRASOL Trial of mirvetuximab soravtansine vs. Investigator’s Choice of Chemo in FRα Positive Platinum-resistant OC Dr Konecny #gyncsm #SGOmtg 1/2 pic.twitter.com/2qovsbfTEK
— Dee Sparacio (@womenofteal) March 16, 2024
Efficacy/ safety of alpelisib + olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial Dr Konstantinopoulos
— Dee Sparacio (@womenofteal) March 16, 2024
Did not meet primary endpt PFS ,#gyncsm #SGOmtg pic.twitter.com/CuWQxOHGhF
A phase II/III study of cediranib & olaparib combo compared to cediranib or olaparib alone or standard of care chemotherapy, in platinum-resistant ovarian cancer (NRG-GY005) Dr Lee #gyncsm #SGOmtg All oral drugs, No difference in PFS, OS between arms. pic.twitter.com/Do1sBwEhUE
— Dee Sparacio (@womenofteal) March 16, 2024
Repair Assisted Damage Detection (RADD) as a potential predictive biomarker for immunotherapy response in ovarian cancer Dr Rocconi #SGOmtg #gyncsm pic.twitter.com/sCUMJmShZB
— Dee Sparacio (@womenofteal) March 16, 2024
Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian cancer after frontline therapy Dr. Knisely, MRD may be used prognostic, SLL vs ctDNA #gyncsm #SGOmtg pic.twitter.com/Z7z9aHY7kA
— Dee Sparacio (@womenofteal) March 16, 2024
Endometrial Cancer
Translational biomarkers of response to Enzalutamide in #endometrialcancer presented by @AnilSoodMD @MDAndersonNews #SGOMtg pic.twitter.com/8MBSB9p8qU
— Nicole D. Fleming MD (@nicoleflemingmd) March 16, 2024
TROP-2 #ADC Sacituzumab in phase II EVER trial from China shows impressive ORR of 50%-No CRs unlike Tidvak (Tissue factor ADC) but PR of 50% vs 24% in TV and comparable DOR 9 vs 8mo in TV. Hmmmm... how to choose if these become available globally #SGOMtg #gyncsm pic.twitter.com/4gSA3rrs2i
— Dr.Monica Avila (@MAvilaMD) March 16, 2024
Ovarian Cancer
Final OS Data- Ph 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combo W/Nab-Paclitaxel in Patients W/ Recurrent Plat-Resistant OC Relacorilant shown to restore chemosensitivity,chance of survival at 24 mo more than double
— Dee Sparacio (@womenofteal) March 16, 2024
Dr Colombo #gyncsm #SGOmtg pic.twitter.com/sEniPGXt4O
Fuzuloparib as maintenance therapy in patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: results from a randomized, placebo-controlled, phase 3 trial
— Dee Sparacio (@womenofteal) March 16, 2024
Dr Wu #gyncsm #SGOMtg Increase PFS in newly dx OC regardless of BRCA status pic.twitter.com/0uPwhkFpnJ
Rapid Fire Poster: Defying platinum resistance: Boosting overall survival in platinum-resistant ovarian cancer patients Dr Piver #gyncsm #SGOmtg pic.twitter.com/IzOzyFAbgf
— Dee Sparacio (@womenofteal) March 16, 2024
Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Rapid Fire Poster Phase II of Weekly Paclitaxel, Lenvatinib and Pembrolizumab in Patients with Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
— Dee Sparacio (@womenofteal) March 16, 2024
Dr Backes
Encouraging activity seen with this combo #gyncsm #SGOmtg pic.twitter.com/OrFqsK3nJ1
Ovarian Cancer
Anlotinib combined w/ carbo/paclitaxel &maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010) Dr Cheng
— Dee Sparacio (@womenofteal) March 16, 2024
favorable efficacy and tolerated safety profile for anlotinib #gyncsm #SGOmtg pic.twitter.com/d8NW200Hr5
Endometrial Cancer
Platinum-free interval (PFI) and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer Retrospective study Dr Haight
— Dee Sparacio (@womenofteal) March 16, 2024
Longer PFI more likely to get plat drugs , associated w/ improved resp in 2nd line #gyncsm #SGOmtg pic.twitter.com/JjVjLVyzGS
Together We Tackle Cancer Session:
Evaluating Differences Among PRAPARE Screening Assessments of Gyn Onc Patients Based on Socio-demographic Factors Dr Kako #gyncsm #SGOMtg
— Dee Sparacio (@womenofteal) March 16, 2024
positive PRAPARE result in higher distress , $ need , general distress pic.twitter.com/TA3E1aq7pp
A Pilot Randomized Controlled Trial of BOLSTER: A Nurse-Led Telehealth Intervention for Patients with Peritoneal Carcinomatosis and their Caregivers
— Dee Sparacio (@womenofteal) March 16, 2024
Dr Pozzar
Proof of concept that BOLSTER is acceptable to patients and may improve QOL #gyncsm #SGOmtg pic.twitter.com/gHswzkobHl
Post-Operative Complications in Elderly Patients Undergoing Surgery for Ovarian Cancer: A NSQIP Analysis Dr Salman
— Dee Sparacio (@womenofteal) March 16, 2024
Higher levels of cardio and pulmonary complications in elderly patients w/OC #gyncsm #SGOmtg pic.twitter.com/DXiKZIao1H
I'll keep you updated on what I learned on Sunday and Monday in the next few days.
Dee
Every Day is a Blessing!
No comments:
Post a Comment